InflaRx (IFRX) Competitors $2.50 -0.02 (-0.79%) As of 10:37 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends IFRX vs. TRML, ANNX, PROK, ALT, XERS, PHAT, MGTX, ARCT, KOD, and TERNShould you be buying InflaRx stock or one of its competitors? The main competitors of InflaRx include Tourmaline Bio (TRML), Annexon (ANNX), ProKidney (PROK), Altimmune (ALT), Xeris Biopharma (XERS), Phathom Pharmaceuticals (PHAT), MeiraGTx (MGTX), Arcturus Therapeutics (ARCT), Kodiak Sciences (KOD), and Terns Pharmaceuticals (TERN). These companies are all part of the "pharmaceutical products" industry. InflaRx vs. Tourmaline Bio Annexon ProKidney Altimmune Xeris Biopharma Phathom Pharmaceuticals MeiraGTx Arcturus Therapeutics Kodiak Sciences Terns Pharmaceuticals InflaRx (NASDAQ:IFRX) and Tourmaline Bio (NASDAQ:TRML) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, community ranking, institutional ownership, profitability, valuation, analyst recommendations and media sentiment. Is IFRX or TRML more profitable? Tourmaline Bio has a net margin of 0.00% compared to InflaRx's net margin of -33,362.70%. Tourmaline Bio's return on equity of -20.97% beat InflaRx's return on equity.Company Net Margins Return on Equity Return on Assets InflaRx-33,362.70% -65.98% -56.86% Tourmaline Bio N/A -20.97%-20.56% Does the MarketBeat Community believe in IFRX or TRML? InflaRx received 222 more outperform votes than Tourmaline Bio when rated by MarketBeat users. However, 100.00% of users gave Tourmaline Bio an outperform vote while only 64.77% of users gave InflaRx an outperform vote. CompanyUnderperformOutperformInflaRxOutperform Votes23964.77% Underperform Votes13035.23% Tourmaline BioOutperform Votes17100.00% Underperform VotesNo Votes Do institutionals & insiders have more ownership in IFRX or TRML? 42.4% of InflaRx shares are held by institutional investors. Comparatively, 91.9% of Tourmaline Bio shares are held by institutional investors. 16.3% of InflaRx shares are held by company insiders. Comparatively, 11.0% of Tourmaline Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has stronger valuation and earnings, IFRX or TRML? Tourmaline Bio has lower revenue, but higher earnings than InflaRx. Tourmaline Bio is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInflaRx$70K2,102.86-$46.18M-$1.08-2.31Tourmaline BioN/AN/A-$42.12M-$2.82-6.18 Does the media prefer IFRX or TRML? In the previous week, InflaRx had 3 more articles in the media than Tourmaline Bio. MarketBeat recorded 7 mentions for InflaRx and 4 mentions for Tourmaline Bio. InflaRx's average media sentiment score of 0.72 beat Tourmaline Bio's score of 0.56 indicating that InflaRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InflaRx 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tourmaline Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer IFRX or TRML? InflaRx currently has a consensus target price of $8.00, suggesting a potential upside of 220.00%. Tourmaline Bio has a consensus target price of $54.00, suggesting a potential upside of 209.99%. Given InflaRx's higher probable upside, equities analysts plainly believe InflaRx is more favorable than Tourmaline Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InflaRx 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Tourmaline Bio 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, IFRX or TRML? InflaRx has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500. Comparatively, Tourmaline Bio has a beta of 2.36, meaning that its stock price is 136% more volatile than the S&P 500. SummaryInflaRx and Tourmaline Bio tied by winning 8 of the 16 factors compared between the two stocks. Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IFRX vs. The Competition Export to ExcelMetricInflaRxPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$147.20M$6.25B$5.20B$9.10BDividend YieldN/A2.94%5.13%4.05%P/E Ratio-2.319.0385.8217.21Price / Sales2,102.86300.291,319.7575.18Price / CashN/A61.4443.8336.01Price / Book1.326.055.314.77Net Income-$46.18M$154.38M$122.56M$225.10M7 Day Performance7.30%-4.32%-1.17%0.09%1 Month Performance8.23%-1.22%1.13%1.69%1 Year Performance51.52%-0.87%26.15%19.34% InflaRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IFRXInflaRx2.2826 of 5 stars$2.50-0.8%$8.00+220.0%+45.7%$147.20M$70,000.00-2.3160Analyst ForecastShort Interest ↑News CoverageGap UpTRMLTourmaline Bio1.5953 of 5 stars$21.66+1.1%$54.00+149.3%-40.2%$555.43MN/A-7.6844Short Interest ↑Gap DownANNXAnnexon1.9082 of 5 stars$5.14-5.0%$15.80+207.4%+1.0%$547.89MN/A-4.9060Short Interest ↑Gap UpPROKProKidney2.2711 of 5 stars$1.84-1.0%$4.50+144.4%-1.9%$536.95MN/A-3.353Positive NewsALTAltimmune2.2735 of 5 stars$7.48+3.0%$20.00+167.4%-45.2%$532.02M$52,000.00-4.8350Positive NewsXERSXeris Biopharma3.7419 of 5 stars$3.56-1.4%$4.87+36.7%+17.0%$530.73M$187.36M-7.91290Positive NewsPHATPhathom Pharmaceuticals2.7925 of 5 stars$7.68-0.8%$23.00+199.5%-5.7%$525.14M$26.27M-1.35110MGTXMeiraGTx4.7083 of 5 stars$6.51+1.4%$23.50+261.0%-10.2%$508.78M$13.93M-5.38300Gap UpARCTArcturus Therapeutics2.1686 of 5 stars$18.72+4.3%$66.75+256.6%-49.4%$507.07M$142.47M-8.43180Analyst ForecastShort Interest ↑Gap UpKODKodiak Sciences2.8604 of 5 stars$9.40+3.1%$8.00-14.9%+173.6%$494.67MN/A-2.5890Short Interest ↑TERNTerns Pharmaceuticals4.177 of 5 stars$5.79+0.7%$18.30+216.1%-21.0%$491.80M$1M-4.9140Positive NewsGap Up Related Companies and Tools Related Companies Tourmaline Bio Competitors Annexon Competitors ProKidney Competitors Altimmune Competitors Xeris Biopharma Competitors Phathom Pharmaceuticals Competitors MeiraGTx Competitors Arcturus Therapeutics Competitors Kodiak Sciences Competitors Terns Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IFRX) was last updated on 1/16/2025 by MarketBeat.com Staff From Our PartnersDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx Please log in to your account or sign up in order to add this asset to your watchlist. Share InflaRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
